LAVA Therapeutics NV (LVTX) - Total Liabilities
Based on the latest financial reports, LAVA Therapeutics NV (LVTX) has total liabilities worth $39.23 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LVTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
LAVA Therapeutics NV - Total Liabilities Trend (2019–2024)
This chart illustrates how LAVA Therapeutics NV's total liabilities have evolved over time, based on quarterly financial data. See LVTX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
LAVA Therapeutics NV Competitors by Total Liabilities
The table below lists competitors of LAVA Therapeutics NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
Turkey | TL4.75 Billion |
|
LGL Group Inc
NYSE MKT:LGL
|
USA | $1.49 Million |
|
Banswara Syntex Limited
NSE:BANSWRAS
|
India | Rs6.99 Billion |
|
Mercal Inmuebles Socimi SA
MC:YMEI
|
Spain | €22.22 Million |
|
Mendus AB (publ)
ST:IMMU
|
Sweden | Skr69.03 Million |
|
Golden House
TA:GOHO
|
Israel | ILA140.96 Million |
|
Dedicare AB (publ)
ST:DEDI
|
Sweden | Skr285.40 Million |
|
Ji-Haw Industrial Co Ltd
TW:3011
|
Taiwan | NT$1.28 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down LAVA Therapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LVTX market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAVA Therapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAVA Therapeutics NV (2019–2024)
The table below shows the annual total liabilities of LAVA Therapeutics NV from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $53.09 Million | +5.05% |
| 2023-12-31 | $50.53 Million | -11.94% |
| 2022-12-31 | $57.38 Million | +174.83% |
| 2021-12-31 | $20.88 Million | +62.30% |
| 2020-12-31 | $12.87 Million | +335.66% |
| 2019-12-31 | $2.95 Million | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more